Who Optimizes SG&A Costs Better? GSK plc or Bio-Techne Corporation

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Bio-Techne Corporation have taken different paths in optimizing these costs. From 2014 to 2023, Bio-Techne's SG&A expenses grew by over 550%, reflecting its aggressive expansion strategy. In contrast, GSK's expenses remained relatively stable, with a modest increase of around 14% over the same period. This suggests a more conservative approach, possibly focusing on efficiency and cost control.

Interestingly, in 2022, GSK's SG&A expenses dropped significantly by approximately 27%, indicating a strategic shift or cost-cutting measures. Meanwhile, Bio-Techne continued its upward trend, reaching its highest SG&A expenses in 2024. The data for 2024 is incomplete for GSK, leaving room for speculation on its future strategy. These trends highlight the diverse strategies companies employ to manage operational costs in a dynamic market.